ReviewBiology2026
Hypoxia-Inducible Factor 1α in Type 2 Diabetes Mellitus: Mechanisms and Therapeutic Perspectives.
Review in Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes mellitus (T2DM) is a global epidemic driven by chronic hyperglycemia, leading to severe microvascular and macrovascular complications. Hypoxia is a critical pathogenic factor, and hypoxia-inducible factor 1α (HIF-1α) serves as a central transcriptional regulator of cellular adaptation to low oxygen. This review examines the dual roles of HIF-1α in T2DM and its complications, including diabetic kidney disease, retinopathy, obesity-related insulin resistance, and impaired wound healing. HIF-1α exerts protective effects by enhancing glycolysis, reducing oxidative stress, and promoting angiogenesis, but it can also be detrimental by driving pathological neovascularization, fibrosis, and chronic inflammation. Its functional outcomes depend on tissue type, disease stage, and metabolic context, posing therapeutic challenges. Emerging pharmacologic strategies aim to fine-tune HIF-1α activity. A deeper understanding of the spatiotemporal regulation of HIF-1α signaling may inform more targeted therapeutic strategies, though considerable preclinical and clinical challenges remain.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.